Popular
This Week This Month
Storyboards
Sign In
to Vote &
Create Storyboards.
 

Phase III trial shows improved survival with TAS-102 in metastatic colorectal cancer refractory to standard therapies

Science Daily - 28 Jun 2014 14:23
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said.
Full Article at Science Daily

More Science News
5
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}     {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}

    • Create Storyboard